Published in J Acquir Immune Defic Syndr on December 01, 2010
Acceptability of pre-exposure prophylaxis among men who have sex with men and transgender women in Northern Thailand. PLoS One (2013) 1.03
Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide. Antimicrob Agents Chemother (2012) 0.86
Experience in international clinical research: the HIV Prevention Trials Network. Clin Investig (Lond) (2011) 0.84
Passing the baton: Community-based ethnography to design a randomized clinical trial on the effectiveness of oral pre-exposure prophylaxis for HIV prevention among Black men who have sex with men. Contemp Clin Trials (2015) 0.78
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1994) 25.02
Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA (2000) 10.17
Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 7.42
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med (1997) 7.11
Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr (2009) 5.48
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep (2001) 5.34
Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr (2008) 5.05
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep (2005) 5.03
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Rethinking prevention of HIV type 1 infection. Clin Infect Dis (2010) 4.19
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr (2004) 3.86
An HIV vaccine--evolving concepts. N Engl J Med (2007) 3.78
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr (2008) 3.10
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2001) 2.84
Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet (2008) 2.75
Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr (2006) 1.93
Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis (2004) 1.78
Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS (1998) 1.59
The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55
Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc (2010) 1.51
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS (2004) 1.44
Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis (1999) 1.32
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology (2007) 1.28
Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect (2001) 1.27
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. PLoS Med (2008) 0.90
HIV prevention trials require sophisticated community preparation. Controversial PrEP trials serve as cautionary tale. AIDS Alert (2009) 0.77
Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS (2010) 2.33
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis (2009) 2.17
Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr (2008) 1.63
Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol (2011) 1.32
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS (2008) 1.26
Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health (2010) 1.25
Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India. Int J Infect Dis (2009) 1.04
Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study. Clin Infect Dis (2009) 0.92
A longitudinal quality-of-life study of HIV-infected persons in South India: the case for comprehensive clinical care and support services. AIDS Educ Prev (2009) 0.90
Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients. J Int Assoc Physicians AIDS Care (Chic) (2011) 0.85
Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting. Int J Infect Dis (2009) 0.83
Challenges of expansion of voluntary counselling and testing in India. Sex Health (2008) 0.82
Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. Int J Infect Dis (2008) 0.81
Opportunities and options for the use of protease inhibitors in a resource-poor setting: experiences from southern India. J Acquir Immune Defic Syndr (2007) 0.80
Clinical outcomes among HIV/tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India. J Int Assoc Provid AIDS Care (2012) 0.78
Expansion of HIV laboratory diagnostic services in Chennai, India 2001-2006: is the growth commensurate with the need? PLoS One (2008) 0.77
The social ecology of HIV/AIDS. Med Clin North Am (2008) 0.77
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. J Acquir Immune Defic Syndr (2007) 0.75
Clinical Risk Factors Associated With Peripartum Maternal Bacteremia. Obstet Gynecol (2017) 0.75
Health care policy under President Romney. N Engl J Med (2012) 0.75